

Special Issue

Extracellular Vesicle-Based Delivery System for Cancer and Neurodegenerative Disease Treatment

Message from the Guest Editors

Extracellular vesicles (EVs) have emerged as promising nanocarriers capable of crossing biological barriers and delivering therapeutic agents with high specificity and reduced toxicity. The most clinically approved delivery vehicles are represented by liposomes, which are EV-like structures sharing structural similarities with EVs, but differing in composition and ease of production. EVs offer greater biological complexity and potential for drug loading, but face manufacturing and quality control challenges. Future applications involve the use of EV-based platforms for the delivery of immunotherapeutics, such as mRNA-based drugs. Overall, the field of EVs could be critical for advancing targeted therapies, which can significantly contribute to improving the outcomes of patients with cancer or neurodegenerative conditions. This Special Issue aims to gather innovative research and comprehensive reviews on the development and application of EV-based delivery systems. We seek to explore the mechanisms, challenges, and clinical potential of these systems (by EVs and EV-like structures), aligning with cutting-edge therapeutic strategies and drug/gene delivery technologies.

Guest Editors

Dr. Eva Costanzi
Dr. Stefano Persano
Prof. Dr. Stefano Leporatti

Deadline for manuscript submissions

15 July 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/210835

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).